

13th
International
Conference
on Reproduction,
Pregnancy
and Rheumatic
diseases

Vienna, Austria
8-10 May 2025

FINAL PROGRAMME



ENDORSEMENTS

This conference is endorsed by



WELCOME MESSAGE

Welcome back to the RheumaPreg Conference 2025, set against the backdrop of Vienna, the enchanting home of Mozart and Freud!

As we assemble for this year's conference, we embark on a comprehensive exploration of the intricate relationship between rheumatic diseases and pregnancy, addressing key challenges and breakthroughs in our evolving understanding. We would like to exchange experiences, catch-up on the past two years, enjoy the springtime over a cup of Viennese coffee with old friends and new colleagues.

We are committed to interdisciplinarity. For this reason, panel discussions and curbside consultations will involve esteemed experts from the fields of rheumatology, obstetrics, haemostasiology, intensive care medicine and neonatology, pathology and patient representatives.

Among others, updates on evolving guidelines, medication use, counselling, use of assisted reproduction techniques, management during and after pregnancy and acute situations will be elaborated and presented together with clinical cases. We will dig down to the root of common problems during pregnancy and learn about immunology and placental pathologies related to rheumatic diseases and complications.

Furthermore, the conference will provide a platform for revisiting teratogenicity of therapies, scrutinizing the latest evidence to ensure an updated perspective on treatment safety during pregnancy, breastfeeding and data about long-term follow up of the children.

Lastly, we will revisit the progress of the existing registries and address the problems associated with the lack of standardized definitions, particularly delving into the complexity of terms like "adverse obstetric outcome" or "disease activity" which pose obstacles in comparing results.

We would like to thank the RheumaPreg 2025 Congress Committee, the organizational team and all members of the RheumaPreg community for their commitment and efforts in shaping this congress. Additionally, we wish to express gratitude to all delegates who will attend and contribute to the Congress in 2025 in Vienna.

Join us in this intellectual journey, where we will not only revisit established knowledge but also navigate the complexities of interdisciplinary management, pose new questions and address the latest developments.

Welcome back to RheumaPreg Vienna 2025 - Together, let's shape the future of rheumatology in pregnancy!

Assoc. Prof. Klara Rosta, PhD
Chair - Obstetrics/Gynecology



Dr. Antonia Mazzucato-Puchner
Chair - Rheumatology



CONGRESS COMMITTEE

CONGRESS CHAIRS

Klara Rosta | Austria

Antonia Mazzucato-Puchner | Austria

LOCAL SCIENTIFIC COMMITTEE

Julia Binder | Austria

Christine Duftner | Austria

Ruth Fritsch-Storck | Austria

Karoline I. Mayer-Pickel | Austria

Judith Sautner | Austria

PAST ORGANIZERS

Catherine Nelson-Piercy | UK

Angela Tincani | Italy

Laura Andreoli | Italy

FACULTY

Silvia Aguilera | Spain

Bonnie Bermas | USA

Mehret Birru Talabi | USA

Lynette Bortey | UK

Irene E.M. Bultink | The Netherlands

Jill Buyon | USA

Christina Chambers | USA

Megan Clowse | USA

Nathalie Costedoat-Chalumeau | France

Elisabeth D'Costa | Austria

Radboud Dolhain | The Netherlands

Anne Drapkin Lyerly | USA

Oseme Etomi | UK

Michael Feichtinger | Austria

Frauke Förger | Switzerland

Ian Giles | UK

Isabell Haase | Germany

Maria Hoeltzenbein | Germany
Elvis Hysa | Italy
Alexandra Kautzky-Willer | Austria
Herbert Kiss | Austria
Katrín Klebermass-Schrehof | Austria
Antonios Makrigiannakis | Greece
Julian Marschalek | Austria
Yvette Meissner | Germany
Arsene Mekinian | France
Anna Molto | France
Louise Moore | Ireland
Marta Mosca | Italy
Olivia Nonn | Germany
Kazem Nouri | Austria
Monika Østensen | Norway
Birgit Pfaller-Eiwegger | Austria
Andea Pluma Sanjurjo | Spain
Vinod Ravindran | India
Jane Salmon | USA
Lisa Rose Sammaritano | USA
Judit Sandor | Austria
Karen Schreiber | Denmark
Savino Sciascia | Italy
Elisabeth Seidl-Mlczoch | Austria
Josef Smolen | Austria
Tanja Stamm | Austria
Jojo Steininger | Austria
Meryam Sugulle | Norway
Bettina Toth | Austria
Anne Trolborg | Denmark
Andrea Ulbrich | Austria
Marianne Wallenius | Norway
Gülen Yerlikaya-Schatten | Austria

PROGRAMME OVERVIEW

Thursday, 8 May 2025 **Room OLYMPIA MANCINI 2+3**

13:00-13:15	Welcome Message
13:15-14:35	Challenges of fertility in context of rheumatic disease and social changes
14:35-15:55	Under the magnifying glass: the placenta as a cause of various pregnancy pathologies
15:55-16:25	Coffee Break
16:25-17:45	Navigating Pregnancy with SLE: Challenges and Innovations
17:45-19:05	Stay updated: news on reproduction with...
19:05-19:25	Opening lecture - beyond rheumatology: ethical issues

Friday, 9 May 2025 **Room OLYMPIA MANCINI 2+3**

08:30-09:30	Inclusion of pregnant people with chronic conditions in research and clinical trials: where do we stand?
09:30-10:40	Beyond the clot: challenges in obstetric Antiphospholipid syndrome
10:40-11:10	Coffee Break
11:10-12:10	Curbside Consultation 1 - Neonatal Lupus
12:10-12:55	Lunch Break
12:55-14:10	Poster tour - Room OLYMPIA MANCINI 1

PROGRAMME OVERVIEW

Friday, 9 May 2025 Room OLYMPIA MANCINI 2+3

14:10-15:10	Immunosuppression during pregnancy
15:30-16:30	The hormonal factor in rheumatic diseases
16:30-17:00	Coffee Break
17:00-18:00	Round table: update on the registries - Prospective cohorts - trials in pregnancy

Saturday, 10 May 2025 Room OLYMPIA MANCINI 2+3

08:30-09:30	INDUSTRY-SPONSORED SYMPOSIUM
09:30-10:15	Debate Session: Gynecologist vs Rheumatologist about immuno modulation for recurrent implantation failure and miscarriage
10:15-10:45	Coffee Break
10:45-11:45	Curbside Consultation 2 - Patient perspectives: family planning with rheumatic diseases
11:45-12:55	Long-term post-partum challenges
12:55-13:25	Gender diversity: inclusivity and the importance of language
13:25-13:40	Closing remarks

LEGENDA

CONGRESS SESSIONS AND ORAL PRESENTATIONS

INDUSTRY-SPONSORED SYMPOSIUM

SCIENTIFIC PROGRAMME

Thursday, 8 May 2025 **Room OLYMPIA MANCINI 2+3**

13:00-13:15

WELCOME MESSAGE

*Chairs: K. Rosta, A. Mazzucato-Puchner (Vienna, Austria)
H. Kiss, J. Smolen (Vienna, Austria)*

13:15-14:35

CHALLENGES OF FERTILITY IN CONTEXT OF RHEUMATIC DISEASE AND SOCIAL CHANGES

*Chairs: I. Haase (Hamburg, Germany),
K. Nouri (Oberpullendorf, Austria),
V. Ravindran (Calicut, India)*

13:15-13:35

Ovarian reserve: current diagnostic and therapeutic options

B. Toth (Innsbruck, Austria)

13:35-13:55

Fertility preservation in rheumatic diseases

J. Marschalek (Vienna, Austria)

13:55-14:15

How to approach infertility in rheumatic diseases

K. Rosta (Vienna, Austria)

14:15-14:25

NORMAL FERTILITY IN WOMEN WITH RHEUMATOID ARTHRITIS AND A WISH TO CONCEIVE WHEN TREATED ACCORDING TO A T2T-APPROACH INCLUDING THE USE OF TUMOR NECROSIS INHIBITORS, AIMED AT REMISSION

C.H. Quaak, E. Röder, H.M. Wintjes,
A.J. Van Steensel-Boon, A.G.M.G. Mulders,
L.J.C. Kranenburg - Van Koppen, L.F. Perez-Garcia,
A.H.J. Danser, R. Dolhain
(Rotterdam, The Netherlands)

14:25-14:35

SAFETY AND EFFICACY OF ASSISTED REPRODUCTIVE TECHNIQUES IN PREGNANT WOMEN WITH SYSTEMIC AUTOIMMUNE DISEASES: EXPERIENCE OF TERTIARY CARE CENTERS OF THE NORTH OF ITALY

V. Canti¹, M.B. Ciona¹, F. Pasi¹, A. Calligaro², F. Ruffilli³,
M. Tonello², E. Giacobbe¹, M.C. Gerardi¹, M. Padovan³,
V.S. Vanni¹, E. Bizzi¹, E. Papaleo¹, B. Maranini³, M. Govoni³,
M. Epis¹, A. Doria², P. Rovere-Querini¹
(¹Milan, Italy; ²Padua, Italy; ³Ferrara, Italy)

SCIENTIFIC PROGRAMME

- 14:35-15:55** **UNDER THE MAGNIFYING GLASS: THE PLACENTA AS A CAUSE OF VARIOUS PREGNANCY PATHOLOGIES**
Chairs: J. Binder (Vienna, Austria), J. Salmon (New York, USA)
- 14:35-14:55 **Placental pathology in systemic lupus erythematosus pregnancies**
I.E.M. Bultink (Amsterdam, The Netherlands)
- 14:55-15:15 **Placental pathology in preeclampsia: what do we know so far**
O. Nonn (Berlin, Germany)
- 15:15-15:35 **Preeclampsia and fetal growth restriction in rheumatic disease: placenta-mediated conditions with short and long-term health consequences**
M. Sugulle (Oslo, Norway)
- 15:35-15:45 **HISTOPATHOLOGICAL PLACENTAL FINDINGS IN ANTIPHOSPHOLIPID ANTIBODY CARRIERS WITH A FETAL LOSS BEYOND 12 WEEKS OF PREGNANCY**
N. Baños¹, S. Dos Santos Beca¹, A. Peguero¹, M. Borrell¹, A. Castellanos², F. Figueras¹, A. Nadal¹, G. Espinosa¹
(¹Barcelona, Spain; ²Jena, Germany)
- 15:45-15:55 **ANGIOGENIC MARKERS IN PLACENTAL TISSUE OF AUTOIMMUNE DISEASE PATIENTS**
P. Fuentes-Zacaria¹, A.S. Castellanos Gutierrez¹, N. Baños², F. Figueras², G. Espinosa², E. Schleußner¹, T. Groten¹, D.M. Morales-Prieto¹
(¹Jena, Germany; ²Barcelona, Spain)
- 15:55-16:25 Coffee break

SCIENTIFIC PROGRAMME

- 16:25-17:45** **NAVIGATING PREGNANCY WITH SLE: CHALLENGES AND INNOVATIONS**
*Chairs: E. D'Costa (Innsbruck, Austria),
C. Nelson-Piercy (London, UK)*
- 16:25-16:45 **How to manage advanced new therapies during pregnancy?**
I. Giles (London, UK)
- 16:45-17:05 **Importance of complement in SLE**
R. Fritsch-Stork (Vienna, Austria)
- 17:05-17:25 **Lupus nephritis and preeclampsia: how to differentiate**
S. Sciascia (Turin, Italy)
- 17:25-17:35 **THE UTILITY OF THE SFLT1: PLGF RATIO TO RULE OUT AND PREDICT PREECLAMPSIA IN WOMEN WITH LUPUS**
M. Clowse, K. Addae-Konadu, J. Federspiel, J. Gilner,
E. Kovalik, A. Lucas, L. Neil, C. Sims, A. Snyderman, A. Eudy
(Durham, USA)
- 17:35-17:45 **ADVERSE PREGNANCY OUTCOME ASSOCIATIONS AMONG WOMEN PRIOR TO DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS**
J. English, B. Wolf, D. Kamen
(Charleston, USA)
- 17:45-19:05** **STAY UPDATED: NEWS ON REPRODUCTION WITH...**
*Chairs: C. Duftner (Vienna, Austria),
A. Molto (Paris, France)*
- 17:45-18:05 **Inflammatory arthritis**
R. Dolhain (Rotterdam, The Netherlands)
- 18:05-18:25 **Connective tissue disorders**
M. Mosca (Pisa, Italy)
- 18:25-18:45 **Vasculitis**
M. Clowse (Durham, USA)

SCIENTIFIC PROGRAMME

18:45-18:55

MATERNAL AND NEONATAL OUTCOMES IN WOMEN WITH SYSTEMIC SCLEROSIS GIVING BIRTH BEFORE AND/OR AFTER DIAGNOSIS - A SWEDISH POPULATION-BASED COHORT STUDY

K. Hellgren¹, I.C. Weng¹, L. Annicchiarico¹, L. Andreoli^{2,3}, O. Stephansson¹, M. Holmqvist¹
(¹Stockholm, Sweden; ²Brescia, Italy; ³Odense, Denmark)

18:55-19:05

MEN WITH IJD ARE YOUNGER WHEN BECOMING FATHERS - IS THERE AN ASSOCIATION BETWEEN ENTERING FATHERHOOD AND DEVELOPING INFLAMMATORY JOINT DISEASE?

G.D. Sigmó¹, S. Hauge², M. Wallenius³, M.B. Lauvsnes¹, H.B. Hetland¹, K.Å. Salvesen³, G. Bakland⁴, A.K.N. Daltveit², B.S. Fevang²
(¹Stavanger, Norway; ²Bergen, Norway; ³Trondheim, Norway; ⁴Tromsø, Norway)

19:05-19:25

OPENING LECTURE - BEYOND RHEUMATOLOGY: ETHICAL ISSUES

Chairs: K. Rosta, A. Mazzucato-Puchner (Vienna, Austria)
A. Drapkin Lyerly (Chapel Hill, USA)

SCIENTIFIC PROGRAMME

Friday, 9 May 2025 **Room OLYMPIA MANCINI 2+3**

- 08:30-09:30** **INCLUSION OF PREGNANT PEOPLE WITH CHRONIC CONDITIONS IN RESEARCH AND CLINICAL TRIALS: WHERE DO WE STAND?**
Chair: L. Andreoli (Brescia, Italy)
- 08:30-08:40 **Regulatory framework of data generation in the United States (FDA): status quo and future prospects for the inclusion of pregnant women in clinical trials**
L. Andreoli (Brescia, Italy)
- 08:40-08:50 **Regulatory framework of data generation in Europe (EMA): status quo and future prospects for the inclusion of pregnant women in clinical trials**
J. Sandor (Vienna, Austria)
- 08:50-09:00 **Obstetric Medicine: practice in an evidence poor zone**
C. Nelson-Piercy (London, UK)
- 09:00-09:30 **Panel discussion: current challenges in generating research data in pregnant and breastfeeding women with chronic rheumatological diseases**
Discussants:
S. Aguilera (Elche, Spain)
C. Nelson-Piercy (London, UK)
K. Rosta (Vienna, Austria)
J. Sandor (Vienna, Austria)
K. Schreiber (Sønderborg, Denmark)
- 09:30-10:40** **BEYOND THE CLOT: CHALLENGES IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME**
*Chairs: N. Costedoat-Chalumeau (Paris, France),
K.I. Mayer-Pickel (Graz, Austria)*
- 09:30-09:50 **Implications of new classification criteria of APS - What does it mean for you?**
K.I. Mayer-Pickel (Graz, Austria), A. Tincani (Brescia, Italy)
- 09:50-10:10 **"Quo vadis" obstetric APS**
K. Schreiber (Sønderborg, Denmark)

SCIENTIFIC PROGRAMME

- 10:10-10:30 **The inhibition of TNF in difficult-to-treat obstetric APS**
J. Salmon (New York, USA)
- 10:30-10:40 **PATIENT PERSPECTIVES ON REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS AND/OR ANTIPHOSPHOLIPID SYNDROME DURING PREGNANCY**
J. Kooiman¹, J. van Woerkom², M. Wind³, O. Teng³, T. Lely², J. Pullen², G. Jansen¹, L. Perez¹, R. Dolhain¹, M. Limper²
(¹Rotterdam, The Netherlands; ²Utrecht, The Netherlands; ³Leiden, The Netherlands)
- 10:40-11:10 Coffee break
- 11:10-12:10 CURBSIDE CONSULTATION 1 – NEONATAL LUPUS**
*Chairs: J. Sautner (Stockerau, Austria),
O. Etomi (London, UK)*
- When to treat? And who and how much should we monitor?**
Presenter: A. Trolborg (Aarhus, Denmark)
Discussants:
J. Buyon (New York, USA)
N. Costedoat-Chalumeau (Paris, France)
E. Seidl-Mlczoch (Vienna, Austria)
G. Yerlikaya-Schatten (Vienna, Austria)
- 12:10-14:10 Lunch break and Poster tour
- 14:10-15:10 IMMUNOSUPPRESSION DURING PREGNANCY**
*Chairs: B. Bermas (Dallas, USA),
A. Mazzucato-Puchner (Vienna, Austria)*
- 14:10-14:30 **2024 Update of EULAR recommendations**
F. Förger (Bern, Switzerland)
- 14:30-14:50 **Biologics during pregnancy**
I. Giles (London, UK)

SCIENTIFIC PROGRAMME

- 14:50-15:10 **Oops, I am pregnant! Teratogenicity and decision making**
M. Hoeltzenbein (Berlin, Germany)
- 15:10-15:20 **ROTAVIRUS VACCINATION DURING THE FIRST 6 MONTHS OF LIFE IN OFFSPRING EXPOSED TO TUMOUR NECROSIS FACTOR INHIBITORS WAS NOT ASSOCIATED WITH AN INCREASED RISK OF DIARRHEA EVENTS DURING THE FIRST 2 YEARS**
L. Flatman, M.E. Beauchamp, Y. St-Pierre, I. Malhamé, A. Bérard, S. Bernatsky, É. Vinet
(Montreal, Canada)
- 15:20-15:30 **THE EFFECT OF BIOLOGIC TREATMENT FOR PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS ON SEMEN PARAMETERS – A LONGITUDINAL STUDY**
A. Polachek, K. Meridor, S. Barda, D. Rosenberg, D. Paran, O. Elkayam
(Tel Aviv, Israel)
- 15:30-16:30 THE HORMONAL FACTOR IN RHEUMATIC DISEASES**
Chairs: A. Kautzky-Willer (Vienna, Austria), M. Østensen (Kristiansand, Norway)
- 15:30-15:50 **The influence of hormones on the course of rheumatic diseases**
E. Hysa (Genoa, Italy)
- 15:50-16:10 **Contraception in rheumatic diseases**
K. Rosta (Vienna, Austria), L. Sammaritano (New York, USA)
- 16:10-16:30 **Menopause - Hormonal therapy and alternatives in rheumatic diseases**
B. Bermas (Dallas, USA)
- 16:30-17:00 Coffee break

SCIENTIFIC PROGRAMME

17:00-18:00

**ROUND TABLE: UPDATE ON THE REGISTRIES -
PROSPECTIVE COHORTS - TRIALS IN PREGNANCY**

*Chairs: C. Chambers (San Diego, USA),
T. Stamm (Vienna, Austria)*

L. Andreoli (Brescia, Italy)

M. Clowse (Durham, USA)

N. Costedoat-Chalumeau (Paris, France)

F. Förger (Bern, Switzerland)

A. Mazzucato-Puchner (Vienna, Austria)

Y. Meissner (Berlin, Germany)

A. Molto (Paris, France)

K. Schreiber (Sønderborg, Denmark)

A. Tincani (Brescia, Italy)

M. Wallenius (Trondheim, Norway)

SCIENTIFIC PROGRAMME

Saturday, 10 May 2025 Room OLYMPIA MANCINI 2+3

08:30-09:30 INDUSTRY-SPONSORED SYMPOSIUM

09:30-10:15 DEBATE SESSION: GYNECOLOGIST VS RHEUMATOLOGIST ABOUT IMMUNOMODULATION FOR RECURRENT IMPLANTATION FAILURE AND MISCARRIAGE

Chairs: M. Feichtinger (Vienna, Austria),

K. Nouri (Oberpullendorf, Vienna)

A. Makrigiannakis (Crete, Greece) **vs** A. Mekinian (Paris, France)

10:15-10:45 Coffee break

10:45-11:45 CURBSIDE CONSULTATION 2 - PATIENT PERSPECTIVES: FAMILY PLANNING WITH RHEUMATIC DISEASES

Chairs: M. Clowse (Durham, USA),

M. Østensen (Kristiansand, Norway)

Pre pregnancy counselling for complex scleroderma

Presenter: C. Nelson-Piercy (London, UK)

Discussants:

S. Aguilera (Elche, Spain)

K. Klebermass-Schrehof (Vienna, Austria)

L. Moore (Dublin, Ireland)

J. Sautner (Stockerau, Austria)

11:45-12:55 LONG-TERM POST-PARTUM CHALLENGES

Chairs: M. Birru Talabi (Pittsburgh, USA),

A. Ulbrich (Vienna, Austria)

11:45-12:05 **Long-term maternal cardiovascular risk: bridging risk assessment and postpartum care**

B. Pfaller-Eiwegger (St. Pölten, Austria)

12:05-12:25 **Lactation with rheumatic diseases: a guide for counselling**

M. Birru Talabi (Pittsburgh, USA)

12:25-12:45 **Long-term follow up of children**

L. Andreoli (Brescia, Italy)

SCIENTIFIC PROGRAMME

12:45-12:55

IMMUNE SYSTEM PROFILE OF NEWBORNS BORN TO MOTHERS TREATED WITH TNF INHIBITORS THROUGH PREGNANCY

Y. Luo¹, A. Freixedas¹, N. Baños¹, D. Acevedo¹, E. Quesada¹, A. Pluma¹, R. Castellanos-Moreira¹, S. Rodríguez-García¹, A. Deyà¹, A. García-García¹, E. Moreno¹, M. Torres¹, M. Casellas¹, D. Grados², M. Juan¹, A. Esteve-Solé¹, L. Alsina¹
(¹Barcelona, Spain; ²Igualada, Spain)

12:55-13:25

GENDER DIVERSITY: INCLUSIVITY AND THE IMPORTANCE OF LANGUAGE

Chair: C. Nelson-Piercy (London, UK)
J. Steininger (Vienna, Austria)

13:25-13:40

CLOSING REMARKS

K. Rosta, A. Mazzucato-Puchner (Vienna, Austria)

POSTERS

Friday, 9 May 2025 - h. 12:55-14:10

Room **OLYMPIA MANCINI 1**

POSTER SESSION 1: ANTIPHOSPHOLIPID SYNDROME: FROM UNDERSTANDING TO EVOLVING MANAGEMENT; ARTIFICIAL REPRODUCTIVE TECHNIQUES AND THE ROLE OF FERTILITY PRESERVATION IN RHEUMATIC DISEASES; CHALLENGES OF FERTILITY IN CONTEXT OF RHEUMATIC DISEASE AND SOCIAL CHANGES

Chairs: K. Rosta (Vienna, Austria), J. Salmon (New York, USA)

PO:01:001 ANTIPHOSPHOLIPID ANTIBODIES IN WOMEN WITH EARLY AND LATE ONSET PREECLAMPSIA

A. Makatsariya¹, J. Khizroeva¹, V. Bitsazde¹, A. Solopova¹, E. Grandone^{1,2}, M. Tretyakova¹, A. Antonova¹, K. Grigoreva¹, N. Gashimova¹, T. Polyakova¹, A. Shatilina¹, E. Lyadnova¹
(¹Moscow, Russia, ²San Giovanni Rotondo, Italy)

PO:01:002 OBSTETRIC OUTCOMES IN A COHORT OF PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES ACCORDING TO ASPIRIN DOSAGE

L. Ibarra Veganzones¹, K. Breen², S. Robinson², B. Hunt², T. Robbins², O. Etomi²
(¹Madrid, Spain, ²London, UK)

PO:01:003 EVOLVING INTO SERONEGATIVE ANTIPHOSPHOLIPIDS SYNDROME. A CASE REPORT FROM BAHRAIN

F. Haji
(Manama, Bahrain)

PO:01:004 PREGNANCY COURSE IN PATIENTS WITH ANTI-PHOSPHOLIPID ANTIBODIES AT THE UNIVERSITY HOSPITAL FREIBURG - A CASE SERIES

C. Glaser, N. Venhoff
(Freiburg, Germany)

PO:01:005 UTERINE ARTERY DOPPLER INDICES IN PREGNANT WOMEN WITH ANTIPHOSPHOLIPID SYNDROME: A RETROSPECTIVE CASE-CONTROL STUDY

M.B. Cilona, V. Canti, F. Pasi, M.T. Castiglioni, S. Girardelli, M. Pozzoni, M. Beschi, G. Gorgone, P. Cavoretto, P. Rovere-Querini
(Milan, Italy)

POSTERS

PO:01:006 PREGNANCY OUTCOMES IN NON-CRITERIA OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: ANALYSIS OF A COHORT OF 91 PATIENTS

S. Beça, N. Baños, M. Borrel, E. Ruiz-Ortiz, A. Pérez-Isidro, R. Cervera, J.C. Reverter, D. Tàssies, G. Espinosa
(Barcelona, Spain)

PO:01:007 EVOLUTION OF THERAPY FOR AUTOIMMUNE DISEASES IN PREGNANCY

S. De Carolis, F. Rizzo, V. Matys, A. Botta, C. Garufi
(Rome, Italy)

PO:01:008 DOES AUTOIMMUNITY HAVE AN IMPACT ON THE CLINICAL OUTCOME OF ASSISTED REPRODUCTIVE TECHNIQUES?

D. Zucchi^{1,2}, C. Tani¹, F. Papini¹, A. Panattoni¹, N. Falchi¹, E. Elefante¹, I. Marzi¹, G. Cascarano¹, S. Gori¹, V. Cela¹, M. Mosca¹
(¹Pisa, Italy, ²Siena, Italy)

PO:01:009 THE ROLE OF COMPLEMENT ACTIVATION IN ADVERSE PREGNANCY OUTCOMES BEYOND THE ANTIPHOSPHOLIPID ANTIBODY SYNDROME

V. Canti, M.B. Cilona, M. Beschi, F. Pasi, M.T. Castiglioni, P. Rovere-Querini
(Milan, Italy)

PO:01:010 PROTEIN PROFILING TO IDENTIFY INFLAMMATORY MARKERS ASSOCIATED WITH FERTILITY IN RA; AN EXPLORATORY STUDY.

B. Van Heeswijk, L.-F. Perez-Garcia, E. Lubberts, R. Dolhain
(Rotterdam, The Netherlands)

POSTERS

PO:01:011 LEUKOCYTE TELOMERE LENGTH IN WOMEN WITH AUTOIMMUNE DISEASES AND ITS RELATIONSHIP WITH PREGNANCY

C. Skinner, A.B. Fiscal-Carvajal, G. Calvo-Anguiano, J. Arenas-Estala, M. Ibarra-Ramirez, M. Castellon-Roman, M.A. Ponce-Santillan, A.M. Ortiz-Rios, M.E. Corral Trujillo, L. Perez-Barbosa, A. Guzman-Lopez, T.I. Guzman-Perez, L.E. Martinez-Garza, G.A. Lopez-Uriarte
(Monterrey, Mexico)

PO:01:012 OVARIAN RESERVE IN RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS AND SPONDYLOARTHRITIS: A LINK TO SUBFERTILITY?

S.D. Rodrigues¹, A.C. Moniz¹, F. Pereira¹, J. Gonçalves¹, B.F. Correia¹, M.I. Neves¹, H. Soares¹, J.C. Branco¹, A. Neto¹, M.H. Lourenço^{1,2}, M. Costa¹
(¹Lisbon, Portugal, ²Santa Maria Da Feira, Portugal)

PO:01:013 THE EFFECTS OF PREDNISOLONE ON PREGNANCY OUTCOMES IN WOMEN UNDERGOING IN VITRO FERTILIZATION

A. Plavsic
(Belgrade, Serbia)

PO:01:014 ASSESSMENT OF OVARIAN RESERVE IN REPRODUCTIVE AGE INDIAN WOMEN WITH SLE USING SERUM AMH LEVELS: PRELIMINARY RESULTS FROM A TERTIARY CARE CENTRE

S. Jain, U.S. Verma, S. Gupta, M. Soneja, U. Kumar, N. Wig
(New Delhi, India)

POSTERS

PO:01:015 COMPARING FERTILITY AND PREGNANCY OUTCOMES BETWEEN WOMEN WITH CHILDHOOD-ONSET AND ADULT-ONSET RHEUMATIC DISEASE

L. Robinson, A. Akinsete, C. Siegel, S. Lieber, Y. Kim, N. Nagpal, M. Lockshin, M. Barbhaiya, L. Sammaritano
(New York, USA)

POSTER SESSION 2: FROM PLACENTA PATHOLOGY TO ADVERSE OBSTETRIC OUTCOME: MECHANISMS AND MANAGEMENT (PREECLAMPSIA, FGR, PLACENTAL INSUFFICIENCY); MANAGEMENT OF RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AXIAL SPONDYLOARTHRITIS, AND JUVENILE IDIOPATHIC ARTHRITIS DURING PREGNANCY

Chairs: I.E.M. Bultink (Amsterdam, The Netherlands), O. Etomi (London, UK)

PO:02:016 PLACENTAL MORPHOLOGY IN PREGNANT PATIENTS WITH RHEUMATIC CONDITIONS COMPARED TO A HEALTHY CONTROL GROUP - A RETROSPECTIVE CASE-CONTROL STUDY

A. Szlatinay, Z. Bago-Horvath, U. Heber, B. Trimmel, S. Dekan, K. Rosta, A. Mazzucato-Puchner
(Vienna, Austria)

PO:02:017 THE ROLE OF PLACENTAL BIOMARKERS AND ULTRASOUND IN THE MANAGEMENT OF OBSTETRIC ANTIPHOSPHOLIPID SYNDROME

D. Dzirba, M. Glinko, M. Skoczynska, K. Gruszecka, M. Szmyrka
(Wroclaw, Poland)

PO:02:018 HYPERTENSIVE GESTATIONAL DISORDERS IN PATIENTS WITH RHEUMATIC DISEASES: OBSTETRICAL OUTCOMES AND LONG-TERM CARDIOVASCULAR EVENTS

P. Semeraro, M. Dolci, F. Crisafulli, M. Filippini, M.G. Lazzaroni, L. Moschetti, C. Nalli, M. Taglietti, C. Loardi, R. Orabona, F. Ramazzotto, S. Zatti, L. Andreoli, A. Tincani, F. Franceschini, M. Fredi
(Brescia, Italy)

POSTERS

PO:02:019 USE OF BIOLOGIC DRUGS FOR INFLAMMATORY ARTHRITIS IN PREGNANCY CORRELATES WITH THE LOWEST RATES OF SMALL FOR GESTATIONAL AGE AND ABNORMAL MID-TRIMESTER UTERINE ARTERY DOPPLERS

S. Suriyakumar, M. Oguntula, R. Akindele, B. Goulden,
G. Woodford, D. Williams, I. Giles, D. Nzelu
(London, UK)

PO:02:020 DIFFERENTIAL DIAGNOSIS OF PERSISTENT PROTEINURIA IN PREGNANCY: A CASE OF UCTD AND PRE-ECLAMPSIA

G. Cascarano¹, D. Zucchi^{1,2}, E. Elefante¹, S. Gori¹, B. Dei¹, B. Ciribè¹,
R. Talarico¹, M. Cazzato¹, D. Giannese¹, C. Tani¹, M. Mosca¹
(¹Pisa, Italy, ²Siena, Italy)

PO:02:021 PREGNANCY OUTCOMES IN WOMEN WITH INFLAMMATORY RHEUMATIC DISEASES: A CROSS-SECTIONAL STUDY

T. Ascensão¹, J. Ferreira², C. Vaz², F. Santos², N. Madeira²,
C. Alves¹
(¹Covilhã, Portugal, ²Guarda, Portugal)

PO:02:022 BARRIERS TO MANAGING RHEUMATOID ARTHRITIS DURING PREGNANCY IN AN ETHNIC MINORITY PATIENT

S. Hadavi, S. Vigneswaran, M. Parisaei, A. Subba
(London, UK)

PO:02:023 BACK TO THE CLINIC? EVALUATING PREGNANCY MANAGEMENT OUTCOMES IN VIRTUAL AND IN-PERSON CARE

J. Tan, M. De Vera, N. Amiri
(Vancouver, Canada)

PO:02:024 PREGNANCY OUTCOMES IN ANTI-SSA/SSB POSITIVE PATIENTS WITH RHEUMATIC DISEASES: A RETROSPECTIVE STUDY FROM A TERTIARY CENTER

C. Rua¹, C. Gomes², A. Feio³, M. Rodrigues², S. Ganhão²,
A. Rocha², S. Monteiro², F. Aguiar², I. Brito²
(¹Vila Nova De Gaia, Portugal, ²Porto, Portugal,
³Vila Nova De Famalicão, Portugal)

POSTERS

PO:02:025 GOOD MENTAL HEALTH THROUGHOUT PREGNANCY AND POSTPARTUM FOR NORWEGIAN WOMEN WITH RHEUMATOID ARTHRITIS. RESULTS FROM THE NATIONWIDE PREGNANCY REGISTER REVNATUS.

I.R. Nilssen, B. Jakobsen, H. Koksvik
(Trondheim, Norway)

PO:02:026 EVALUATING THE IMPACT OF BRITISH SOCIETY FOR RHEUMATOLOGY GUIDELINES ON PREGNANCY OUTCOMES IN RHEUMATOID ARTHRITIS: A SINGLE CENTRE EXPERIENCE

T. Mitra¹, B. Goulden¹, G. Woodward¹, S. Jain², S. Leiner³,
H. Nguyen¹, D. Nzelu¹, D. Williams¹, I. Giles¹
(¹London, UK, ²New Delhi, India, ³Vienna, Austria)

PO:02:027 DESCRIPTIVE ANALYSIS FROM THE PREGNANCY CLINIC AT THE DEPARTMENT OF RHEUMATOLOGY, ODENSE UNIVERSITY HOSPITAL

H.M. Lindegaard, C.T. Præstegaard, A.B. Voss
(Odense, Denmark)

PO:02:028 THE INFLUENCE OF INTERDISCIPLINARY PERIPARTUM COUNSELLING AND CARE OF PATIENTS WITH INFLAMMATORY RHEUMATIC JOINT DISEASES ON MEDICATION INTAKE AND RELAPSE FREQUENCY - A RETROSPECTIVE STUDY AT THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY OF THE MEDICAL UNIVERSITY OF VIENNA

L. Hwezda, M. Horvath, V. Ritschl, V. Falcone,
A. Mazzucato-Puchner, K. Rosta
(Vienna, Austria)

PO:02:029 RATES OF FLARE, PREGNANCY OUTCOMES AND COMPLICATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB VERSUS OTHER TNF INHIBITORS

M. Gregori, T. Robbins, O. Etomi
(London, UK)

POSTERS

PO:02:030 IMPACT OF RHEUMATOID ARTHRITIS ON PREGNANCY OUTCOMES AND DISEASE EXACERBATION: INSIGHTS FROM THE PREISE-H REGISTRY

I. Fujioka, T. Chinatsu, G. Mikako
(Setagaya, Japan)

POSTER SESSION 3: GENDER MEDICINE; IMMUNOSUPPRESSIVE THERAPY OF RHEUMATIC DISEASES DURING PREGNANCY AND LACTATION; LONG-TERM FOLLOW UP OF CHILDREN

Chairs: L. Andreoli (Brescia, Italy), A. Mazzucato-Puchner (Vienna, Austria)

PO:03:031 EFFECTS OF JAK INHIBITORS ON MENSTRUAL CYCLE CHARACTERISTICS IN PATIENTS WITH RHEUMATOID ARTHRITIS

A. Napoletano, F. Arezzo, M. Fornaro, G. Lopalco, G. Cormio,
V. Venerito, F. Iannone
(Bari, Italy)

PO:03:032 JANUS KINASE INHIBITOR EXPOSURE DURING PREGNANCY IN IMMUNE-MEDIATED INFLAMMATORY DISEASES: A CASE SERIES OF 3 PATIENTS

A. Needham, J. Tan, V. Cheng, M. De Vera, N. Amiri
(Vancouver, Canada)

PO:03:033 OCULAR TOXICITY FOLLOW-UP USING OPTICAL COHERENCE TOMOGRAPHY (OCT) OF CHILDREN BORN FROM PATIENTS WITH RHEUMATIC DISEASES TREATED WITH HYDROXYCHLOROQUINE VIA OCT - A PROSPECTIVE COHORT STUDY

A. Szlatinay, E. Stifter, K. Rosta, A. Mazzucato-Puchner
(Vienna, Austria)

POSTERS

PO:03:034 INTERNATIONAL REGULATORS ADVICE ON REPRODUCTION AND ANTI-RHEUMATIC DRUGS (REREAD): A STUDY ON INTERPRETATIONS OF LANGUAGE PHRASING

N.S. Schmidt¹, H. Ozawa², A. Abou-Raya³, N. Agmon-Levin⁴, D. Andrade⁵, D. Dey⁶, Y. Meissner⁷, F. Signorelli⁸, T. Vargas⁹, L.F. Perez⁹, L. Andreoli¹⁰, K. Schreiber¹

(¹Sønderborg, Denmark, ²Tokyo, Japan, ³Alexandria, Egypt, ⁴Tel Hashomer, Israel, ⁵São Paulo, Brazil, ⁶Accre, Ghana, ⁷Berlin, Germany, ⁸Rio De Janeiro, Brazil, ⁹Rotterdam, The Netherlands, ¹⁰Brescia, Italy)

PO:03:035 USE OF TUMOR NECROSIS FACTOR INHIBITOR, PREDNISONE, SULFASALAZINE AND HYDROXYCHLOROQUINE DO NOT DIRECTLY ALTER TRANSPLACENTAL IGG TRANSPORT IN PREGNANT WOMEN WITH INFLAMMATORY ARTHRITIS

C.H. Quaak, L.F. Perez, A.H.J. Danser, R.J.E.M. Dolhain (Rotterdam, The Netherlands)

PO:03:036 EFFICACY OF COMBINED THERAPY WITH CORTICOSTEROIDS, IVIG, AND HYDROXYCHLOROQUINE IN PREVENTING FETAL ATRIOVENTRICULAR BLOCK IN ANTI-RO POSITIVE PREGNANCIES: A CASE REPORT.

F. Locati, C. Lubrano, E. Bizzi, N. Cesano, L. Trespidi, M.W. Ossola, M.C. Gerardi, A.L. Brucato, I. Cetin (Milan, Italy)

PO:03:037 FERTILITY AND PREGNANCY OUTCOMES AFTER CAR T-CELL THERAPY: INSIGHTS FROM A LITERATURE REVIEW

P. Kremer, M.-T. Holzer, N. Ruffer, M. Krusche, I. Haase (Hamburg, Germany)

PO:03:038 SAFETY OF BDMARDS DURING PREGNANCY IN PATIENTS WITH RHEUMATIC DISEASES AND ITS IMPACT IN NEWBORNS: DATA FROM A TERTIARY CENTRE

C. Gomes¹, C. Rua², A. Feio³, A. Rocha¹, S. Monteiro¹, M. Rodrigues¹, S. Ganhão¹, F. Aguiar¹, I. Brito¹

(¹Porto, Portugal, ²Vila Nova De Gaia, Portugal, ³Vila Nova De Famalicão, Portugal)

POSTERS

PO:03:039 USE OF BDMARDS DURING PREGNANCY AFTER PRECONCEPTION COUNSELING IN SPANISH PATIENTS WITH RHEUMATIC DISEASES

A. García-Fernández, F. Rengifo-García, R. Senosiain-Echarte, M. Álvaro-Navidad, M.A. González-Gay, J.A. Martínez-López
(Madrid, Spain)

PO:03:040 LIVE VACCINES IN CHILDREN EXPOSED TO TNF-INHIBITORS IN UTERO: EXPERIENCE OF A TERTIARY CENTRE

A. Feio¹, C. Gomes², C. Rua³, S. Ganhão², A. Rocha², S. Bessa Monteiro², M. Rodrigues², F. Aguiar², I. Brito²
(¹Vila Nova De Famalicão, Portugal, ²Porto, Portugal, ³Vila Nova De Gaia, Portugal)

PO:03:041 VARIATIONS IN TACROLIMUS WHOLE BLOOD CONCENTRATIONS DURING PREGNANCY AND ITS IMPLICATIONS FOR THERAPEUTIC DRUG MONITORING: A SYSTEMATIC REVIEW AND META-ANALYSIS

R. Farhat, A. Mendel, I. Malhamé, A. Grunbaum, S. Bernatsky, É. Vinet
(Montreal, Canada)

PO:03:042 THE ROLE OF BIOLOGICAL THERAPY ON PREGNANCY OUTCOMES IN WOMEN WITH INFLAMMATORY RHEUMATIC DISEASES

M.B. Cilona, V. Canti, F. Pasi, S. Rosa, M.T. Castiglioni, P. Rovere-Querini
(Milan, Italy)

PO:03:043 CHANGES IN THE USE OF TNF-INHIBITORS BEFORE, DURING AND AFTER PREGNANCY FROM 2006-2024 IN WOMEN WITH PSORIATIC ARTHRITIS

H. Bjørngaard, H. Koksvik, B. Jakobsen, M. Wallenius
(Trondheim, Norway)

POSTERS

PO:03:044 A CASE OF REFRACTORY AUTOIMMUNE HEPATITIS RELAPSED DURING PREGNANCY

M. Beschi, G. Gorgone, V. Canti, M.B. Cilona, M. Castiglioni,
M. Pozzoni, S. Girardelli, S. Rosa, P. Cavoretto, P. Rovere-Querini
(Milan, Italy)

PO:03:045 OUTCOMES OF CHILDREN BORN TO WOMEN WITH AXIAL SPONDYLARTHROSIS WITH AND WITHOUT IN UTERO EXPOSURE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS

I. Santos, I. Genrinho, S. Reis, N. Martins
(Viseu, Portugal)

POSTER SESSION 4: MYOSITIS, SCLERODERMA, SJÖGREN'S AND VASCULITIS IN PREGNANCY

Chairs: I. Haase (Hamburg, Germany), R. Dolhain (Rotterdam, The Netherlands)

PO:04:046 PREGNANCY OUTCOMES AND PLACENTAL FINDINGS IN WOMEN WITH IGA VASCULITIS: A CASE-CONTROL STUDY

M.D.C. Zamora Medina, E.I. Mendoza Ríos,
D.Y. Copado Mendoza, M.I. Lumbreras Márquez,
O.A. Orozco Guillén, M.J. Rodríguez Sibaja, S. Acevedo Gallegos
(Mexico City, Mexico)

PO:04:047 COMPLETE FETAL ATRIOVENTRICULAR BLOCK ASSOCIATED WITH SJÖGREN'S SYNDROME DURING PREGNANCY

M. Videnie, C.V. Poalelungi, A.V. Bobirca, M.-C. Alexandru,
I. Ceausu
(Bucharest, Romania)

PO:04:048 DE QUERVAIN'S THYROIDITIS IN ANTI-MDA5 ANTIBODY SECRETING AMYOPATHIC DERMATOMYOSITIS

R. Thurs, J. Cortez
(Baguio City, Philippines)

POSTERS

PO:04:049 CASE SERIES OF SIX PATIENTS WITH INFLAMMATORY MYOSITIS SEEN AT A SPECIALIZED PREGNANCY AND RHEUMATIC DISEASES CLINIC

N. Shahtalebi, S. Rieger-Torres, J. Tan, A. Needham, K. Huang, N. Amiri
(Vancouver, Canada)

PO:04:050 DYSREGULATION OF IMMUNE CHECKPOINT MOLECULES IS CHARACTERISTIC IN AUTOIMMUNE CONGENITAL HEART BLOCK

A.L. Stefanski, H. Rincon-Arevalo, N. Nomovi, J. Ritter, T. Dörner
(Berlin, Germany)

PO:04:051 PREGNANCY OUTCOMES IN CONNECTIVE TISSUE DISEASES: A 30-YEAR STUDY OF 465 CASES FROM A SINGLE-CENTER SPANISH REGISTRY

C. Sieiro Santos, J. Ordas Martinez, C. Moriano Morales, C. Alvarez Castro, E. Diez Alvarez
(León, Spain)

PO:04:052 LIFE-THREATENING MYOSITIS IN PREGNANCY: THREE WOMEN WITH THREE DIFFERENT CHOICES AND PREGNANCY OUTCOMES

S. Sheokand, S. Jain, N. Varun, M. Soneja, N. Wig
(New Delhi, India)

PO:04:053 PREGNANCY OUTCOMES IN IDIOPATHIC INFLAMMATORY MYOPATHIES: A NATIONAL MULTICENTRIC STUDY FROM PORTUGAL

A.R. Ribeiro Lopes¹, A. Chicharo^{1,2}, C. Abreu³, S. Dias Rodrigues¹, I. Santos⁴, F. Paramés¹, M. Pulido-Valente¹, M. Centeno¹, L. Pinto¹, S. Barreira¹, R. Marques¹, R. Cruz-Machado¹, S. Capela¹
(¹Lisbon, Portugal, ²Faro, Portugal, ³Almada, Portugal, ⁴Viseu, Portugal)

PO:04:054 ANTENATAL AND INTRAPARTUM CARE IN TAKAYASU'S ARTERITIS

T. Oosterhouse, S. El Hamamy, H. Naseem
(Bangor, UK)

POSTERS

PO:04:055 DISEASE OUTCOME DURING THE POSTPARTUM PERIOD IN SYSTEMIC SCLEROSIS AND UNDIFFERENTIATED CONNECTIVE TISSUE DISEASES: A RETROSPECTIVE SINGLE-CENTRE STUDY OVER 30 YEARS

E. Piovani, L. Moschetti, C. Barison, E. Pedretti, P. Semeraro, L. Andreoli, A. Tincani, F. Franceschini, M.G. Lazzaroni, P. Airò (Brescia, Italy)

PO:04:056 OBSTETRICAL OUTCOMES OF WOMEN AFFECTED BY SCLERODERMA

V. Matys, C. Mandosi, C. Galli, M. Briante, C. Di Dio, E. Noce, C. Cusumano, L. Mastromanno, I. Fischetti, V. Riccieri, R. Priori, M.G. Piccioni (Rome, Italy)

PO:04:057 GRANULOMATOSIS WITH POLYANGIITIS AND THE COURSE OF PREGNANCY: RESULTS FROM THE NATIONWIDE PREGNANCY REGISTER REVNATUS

B. Jakobsen, H.S. Koksvik, T.T. Pedersen, M. Wallenius (Trondheim, Norway)

PO:04:058 PREGNANCY OUTCOMES IN SYSTEMIC SCLEROSIS: EXPERIENCE OF A RHEUMATOLOGY-OBSTETRIC MULTIDISCIPLINARY CLINIC

A. Chícharo, A.R. Lopes, S. Barreira, P. Martins, A.R. Cruz-Machado, L. Pinto, S. Capela (Lisbon, Portugal)

PO:04:059 MIXED CONNECTIVE TISSUE DISEASE AND PREGNANCY: LESSONS FROM 14 YEARS OF MULTIDISCIPLINARY CARE

A. Chícharo, A.R. Lopes, S. Barreira, P. Martins, A.R. Cruz-Machado, L. Pinto, S. Capela (Lisbon, Portugal)

POSTERS

POSTER SESSION 5: REVISITING OSTEOPOROSIS IN REPRODUCTIVE YEARS; SUPPORTING NEW MOTHERS WITH RHEUMATIC DISEASES: POST-PARTUM CHALLENGES; UPDATE ON THE REGISTRIES; PATERNAL RHEUMATIC DISEASE AND MEDICATION-INFLUENCE ON FAMILY PLANNING

Chairs: J. Sautner (Stockerau, Austria), C. Chambers (San Diego, USA)

PO:05:060 A MALE PATIENT WITH ACTIVE RHEUMATOID ARTHRITIS AND A DESIRE TO CONCEIVE BY IN VITRO FERTILISATION

M. Pap, K. Kovac Durmis, I. Zagar, N. Laktasic Zerjavic, P. Peric
(Zagreb, Croatia)

PO:05:061 MALE PERSPECTIVES ON ANTI-RHEUMATIC DRUG USE DURING PERI-CONCEPTION

J. Kronick, D. Mahendra
(Toronto, Canada)

PO:05:062 REPRODUCTIVE HEALTH AND LIFE EVENT PLANNING IN MALE RHEUMATOID ARTHRITIS PATIENTS: INSIGHTS FROM THE PRAISE-H STUDY

M. Goto, I. Fujioka, C. Takai
(Tokyo, Japan)

PO:05:063 MALE PERSPECTIVE ON REPRODUCTIVE HEALTH IN RHEUMATOLOGY PATIENTS: A CROSS-SECTIONAL STUDY

C. Gagliardi, M.C. Gerardi, E. Giacobbe, N. Ughi, S. Benedetti, G. Di Raimondo, A. Ascione, M. Barichello, O. Epis
(Milan, Italy)

PO:05:064 PREGNANCY ASSOCIATED OSTEOPOROSIS: A CASE PRESENTATION

S. Al Emadi, N. Abdulla
(Doha, Qatar)

PO:05:065 A UK TERTIARY REFERRAL UNIT EXPERIENCE OF PREGNANCY AND LACTATION OSTEOPOROSIS (PLO)

H. Irvine, S. Williams
(Oxford, UK)

POSTERS

PO:05:066 NOT ONLY PREGNANCY IS AT RISK OF COMPLICATIONS IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES: A FOCUS ON POSTPARTUM EXPERIENCE IN A REFERRAL CENTER

D. Zucchi^{1,2}, B. Ciribè¹, F. Monacci¹, E. Elefante¹, C. Ietto¹,
G. Cascarano¹, S. Gori¹, V. Gelsi¹, C. Tani¹, M. Mosca¹
(¹Pisa, Italy, ²Siena, Italy)

PO:05:067 ARE MOMS-TO BE WITH RHEUMATIC DISEASES CAPABLE TO DEVELOP A MATERNAL ANTENATAL ATTACHMENT TO THEIR UNBORN BABIES?

C. Skinner, M.E. Corral-Trujillo, R.A. Cerda-Rodriguez,
L.C. Berlanga-Muñoz, B.U. Montes-Rodríguez,
A. Carrasco-Chapa, J.A. Cárdenas-de la Garza, L. Pérez-Barbosa,
D.A. Galarza-Delgado
(Monterrey, Mexico)

PO:05:068 INTENTIONS TO BREASTFEED, PATTERNS AND ATTITUDES IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES IN MEXICO: A MULTICENTER STUDY

C. Skinner¹, M.d.C. Canseco-Larios², A. Lobato-Belmonte²,
D. Ramos¹, L. Perez-Barbosa¹, L. De-la-Rosa²,
A. Carrasco-Chapa¹, A. Gastelum-Strozzi²,
G. Rodriguez-Orozco¹, A.G. Rodriguez-Flores¹,
M.J. Morales-Graciano², M.F. Ramírez- Flores²,
A. Hernandez-Garduno², I. Peláez-Ballestas²
(¹Monterrey, Mexico, ²Mexico City, Mexico)

PO:05:069 BODY SHAPE IMAGE AND SELF-ESTEEM AS PREDICTORS OF POSTPARTUM DEPRESSION IN WOMEN WITH RHEUMATIC DISEASES

L. Perez-Barbosa, C. Skinner-Taylor, G. Rodriguez-Orozco,
A.G. Rodriguez-Flores, M.A. Ponce-Santillan, A.M. Ortiz-Rios,
A. Carrasco-Chapa, L.C. Berlanga-Muñoz, A. Cantu-Balboa,
M.E. Corral-Trujillo, J.A. Cardenas-de la Garza,
D.A. Galarza-Delgado
(Monterrey, Mexico)

POSTERS

PO:05:070 ONE THIRD OF WOMEN WITH INFLAMMATORY RHEUMATIC DISEASES HAVE PROBLEMS CARING FOR THEIR CHILD

Y. Meissner¹, T. Filla², J.G. Richter², T. Ellmann¹, P. Aries³,
C. Glaser⁴, J. Henes⁵, M. Schneider²,
S. Späthling-Mestekemper⁶, C. Specker⁷, A. Zink¹,
R. Fischer-Betz², A. Strangfeld¹
(¹Berlin, Germany, ²Düsseldorf, Germany, ³Hamburg, Germany,
⁴Freiburg, Germany, ⁵Tübingen, Germany, ⁶München, Germany,
⁷Essen, Germany)

PO:05:071 REPRODUCTIVE-AGE-SPECIFIC RHEUMATOID ARTHRITIS REGISTRY FOCUSING ON PATIENT- REPORTED OUTCOMES IN JAPAN

C. Takai, F. Izumi, M. Goto
(Tokyo, Japan)

PO:05:072 PREGNANCY IN UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE (UCTD): MATERNAL DISEASE COURSE, OBSTETRIC COMPLICATIONS AND PERINATAL OUTCOMES IN THE PROSPECTIVE ITALIAN P-RHEUM.IT STUDY

F.R. Ruffilli¹, A. Bortoluzzi^{1,2}, M. Gerosa², B. Maranini¹, M. Zen³,
C. Tani⁴, F. Serale⁵, V. Ramoni⁶, G. Cuomo⁷, M.C. Gerardi², V. Canti²,
A. Iuliano⁸, M.S. Cutro⁹, O.b.o.t. P-RHEUM.it Investigators²,
C. Di Nicola², D. Rozza², C.A. Sciré², A. Tincani¹⁰, L. Andreoli¹⁰,
M. Padovan¹
(¹Ferrara, Italy, ²Milano, Italy, ³Padua, Italy, ⁴Pisa, Italy, ⁵Cuneo, Italy,
⁶Lodi, Italy, ⁷Naples, Italy, ⁸Roma, Italy, ⁹Potenza, Italy,
¹⁰Brescia, Italy)

PO:05:073 FETAL-HOPE STUDY: HOME MONITORING OF FETAL HEART RATE IN SSA + PREGNANT WOMEN. REGISTRY UPDATE.

A.L. Brucato¹, E. Bizzi¹, A. Mauro¹, M.C. Gerardi¹, R. Mascolo¹,
M. Quartarone¹, M. Nivuori¹, R. Milazzo¹, M. Fredi²,
C. Caccia Dominioni¹, L. Serati¹, I. Cetin¹
(¹Milan, Italy, ²Brescia, Italy)

POSTERS

PO:05:074 FUNCTIONAL OUTCOMES IN PREGNANT PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES USING HAQ-DI: A REGISTRY-BASED ANALYSIS

S. Al Emadi, E. Satti, N. Hadwan, B. Jamshaid, A. Padmakumari, O. Alsaed, S. Mohamed, H. Ashoor
(Doha, Qatar)

POSTER SESSION 6: PREGNANCY WITH LUPUS I

Chairs: C. Nelson-Piercy (London, UK), K.I. Mayer-Pickel (Graz, Austria)

PO:06:075 PREGNANCY IN SLE - SHARED DECISION AND TREATMENT, CASES FROM CLINICAL PRACTICE

B. Zhelezarova¹, T. Petranova², N. Stancheva¹
(¹Pleven, Bulgaria, ²Sofia, Bulgaria)

PO:06:076 MATERNAL VASCULAR MALPERFUSION IN LUPUS PREGNANCIES: ASSOCIATION WITH NEONATAL AND FETAL ADVERSE OUTCOMES

M.d.C. Zamora Medina, A.J. Lopez Diaz, M.I. Lumbreras Márquez, M.J. Rodriguez Sibaja, D.Y. Copado Mendoza, O.A. Orozco Guillen, M.L. Palafox Vargas, A. Santiago Diaz, Z. Garcia Alcudia, S. Acevedo Gallegos
(Mexico City, Mexico)

PO:06:077 DAPIROLIZUMAB PEGOL, A NOVEL CD40L INHIBITOR, SHOWED NO ADVERSE OUTCOMES IN AN IN VIVO NON-HUMAN PRIMATE REPROTOXICITY STUDY AND DISPLAYED MINIMAL TO NO HUMAN PLACENTAL TRANSFER IN AN EX VIVO STUDY

L. Renshall¹, B. Hirschmugl², B. Potthoff³, E. Coursaud³, P. Bonnaillie³, S. Kettell³, V. Snoeck³, E. Smith⁴, F. Fallah-Arani⁴, A. Shock⁴, A. Wolfreys⁴, C. Wadsack², P. Brownbill¹
(¹Manchester, UK, ²Graz, Austria, ³Braine-Lalleud, Belgium, ⁴Slough, UK)

POSTERS

PO:06:078 OVERWEIGHT AND OBESITY ARE KEY MODIFIABLE RISK FACTORS FOR ADVERSE OUTCOMES IN SLE PREGNANCIES

E. Vinet¹, K. Sacre², A. Clarke³, M. Barber³, P. Fortin⁴, J. Hanly⁵, A. Legge⁵, S.C. Bae⁶, S. Bernatsky¹

(¹Montreal, Canada, ²Paris, France, ³Calgary, Canada, ⁴Quebec City, Canada, ⁵Halifax, Canada, ⁶Seoul, South Korea)

PO:06:079 THE CLINICAL UTILITY OF SERUM BAFF LEVELS IN PREGNANT PATIENTS WITH SLE

C. Sims¹, A. Eudy¹, S. Soneji¹, K. Addae-Konadu², J. Gilner¹, A. James¹, J. Federspiel¹, E. Kovalik¹, A. Lucas¹, L. Neil¹, A. Snyderman¹, M. Clowse¹

(¹Durham, USA, ²Atlanta, USA)

PO:06:080 ANTI-RO/LA LEVELS IN MOTHERS AND NEONATES CORRELATE WITH INTERFERON SCORES AND EXPRESSION OF INDIVIDUAL GENES IN NEONATES

L. Rudolph, M. Hedlund, E. Richardsdotter Andersson, V. Ottosson, J. Tingström, F. Nordenstam, G. Bergman, S.-E. Sonesson, G.E. Thorlacius, M. Wahren-Herlenius (Stockholm, Sweden)

PO:06:081 DECODING THE CYTOKINE SIGNATURES OF PREGNANCIES WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS

T.T. Pedersen, A. Hagen Jarmund, H.J. Tokle Lien, B. Jakobsen, B. Steinkjer, G. Fanneløb Giskeødegård, M. Høyseter Fenstad, M. Wallenius, A.C. Iversen, M. Haug (Trondheim, Norway)

PO:06:082 THE IMPACT OF PREGNANCY PLANNING ON THE PREVALENCE OF ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE STUDY FROM THREE JAPANESE TERTIARY REFERRAL CENTERS

T. Nakai¹, N. Honda¹, Y. Hashimo², E. Soga¹, S. Fukui^{1,3}, A. Kitada^{1,4}, K. Nakanishi², N. Yokogawa¹, M. Okada¹

(¹Tokyo, Japan, ²Okinawa, Japan, ³Boston, USA, ⁴Ibaraki, Japan)

POSTERS

- PO:06:083 IMPACT OF ORGAN DAMAGE ON PREGNANCY OUTCOMES, AND THE PROGRESSION OF ORGAN DAMAGE DURING PREGNANCY IN PREGNANT WITH SYSTEMIC LUPUS ERYTHEMATOSUS**
T. Nakai¹, S. Fukui^{1,2}, A. Kitada^{1,3}, M. Okada¹
(¹Tokyo, Japan, ²Boston, USA, ³Ibaraki, Japan)
- PO:06:084 DOES GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORES PREDICT PREGNANCY OUTCOME IN SYSTEMIC LUPUS ERYTHEMATOSUS?**
M. Nagy-Vincze, T. Tarr
(Debrecen, Hungary)
- PO:06:085 THE IMPACT OF PREGNANCY PLANNING FOR SYSTEMIC LUPUS ERYTHEMATOSUS: THE PERSPECTIVES FROM A JAPANESE NATIONWIDE PROSPECTIVE LUPUS PREGNANCY COHORT**
E. Miyagawa¹, K. Kaneko², A. Higuchi², S. Isojima²,
M. Matsushita², K. Oku³, Y. Iwata⁴, K. Fujio², T. Miyamae²,
K.-e. Sada⁵, K. Ichinose⁶, A. Nakajima⁷, Y. Tanaka⁸, A. Murashima⁹
(¹Kumamoto, Japan, ²Tokyo, Japan, ³Sagamihara, Japan,
⁴Kanazawa, Japan, ⁵Nankoku, Japan, ⁶Izumo, Japan,
⁷Tsu, Japan, ⁸Kitakyushu, Japan, ⁹Saitama, Japan)
- PO:06:086 DO ALL PREGNANCIES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS HAVE THE SAME RISK?**
N. Martínez Sánchez, S. Ruiz Martínez, M. De La Calle,
Á. Robles Marhuenda, A. Domínguez Cob,
M.L. Muner Hernando, N. Mateos Canals, M. Calvo Alemán,
E. Martín Boado, J.L. Bartha Rasero
(Madrid, Spain)
- PO:06:087 MANAGEMENT OF PREGNANCY IN A WOMAN WITH LUPUS NEPHRITIS AND PROGRESSIVE RENAL DYSFUNCTION: A CASE REPORT.**
F. Locati, N. Cesano, C. Lubrano, L. Trespidi, B. Zaina, V. Binda,
F. Parisi, M.W. Ossola, I. Cetin
(Milan, Italy)

POSTERS

PO:06:088 NO DIFFERENCE IN DAMAGE ACCRUAL BETWEEN SLE-PATIENTS WHO HAVE EVER OR NEVER BEEN PREGNANT

B. Geertsema¹, J. Kooiman², T. Lely¹, K. Bloemenkamp¹,
M. Limper¹

(¹Utrecht, The Netherlands, ²Rotterdam, The Netherlands)

POSTER SESSION 7: PREGNANCY WITH LUPUS 2; NAVIGATING TERATOGENIC TERRAIN: CONTRACEPTION AND MANAGEMENT OF UNINTENDED PREGNANCY

Chairs: R. Fritsch-Stork (Vienna, Austria), B. Bermas (Dallas, USA)

PO:07:089 QUALITY IMPROVEMENT INITIATIVE TO INCREASE AND STANDARDIZE CONTRACEPTION DOCUMENTATION FOR REPRODUCTIVE-AGED WOMEN ACROSS A LARGE ACADEMIC RHEUMATOLOGY DIVISION

C. Siegel, E. Wu, A. Mikhaylov, A.M. Rakowicz, K. Wong, A. Little,
J. Bugante, L. Sembrano, E. Abramson, D. Jannat-Khah,
L. Sammaritano, N. Pan

(New York, USA)

PO:07:090 THE USE OF CONTRACEPTIVE METHODS IN WOMEN WITH RHEUMATOID ARTHRITIS - RESULTS FROM REVNATUS

H.S. Koksvik, B. Jakobsen, I.R. Nilssen, M. Wallenius

(Trondheim, Norway)

PO:07:091 ORAL CONTRACEPTIVE PILL USE IS ASSOCIATED WITH LOWER LEVELS OF NEUTROPHIL EXTRACELLULAR TRAPS

D. Marcy, K. Sturm, C. Lugo, J. Zell, K. Demoruelle

(Aurora, USA)

PO:07:092 CLINICAL INTERVENTIONS TO IMPROVE CONTRACEPTION COUNSELING IN AN ACADEMIC RHEUMATOLOGY PRACTICE

D. Marcy¹, T. Skorupa², K. Sturm¹, K. Demoruelle¹, J. Zell¹

(¹Aurora, USA, ²Boston, USA)

POSTERS

- PO:07:093 SINGLE-CELL RNA SEQUENCING OF PREGNANT WOMEN WITH SPRA AND SLE: UNCOVERING CELL-INDEPENDENT IFN SIGNATURES IN SLE AND A KEY ROLE OF MAIT AND CD4 T-CELLS IN SPRA.**
H. Lien, T.T. Pedersen, B. Jakobsen, A. Flatberg, G. Vatne Leirvik, M. Haug, M. Høysæter Fenstad, P. Sætrom
(Trondheim, Norway)
- PO:07:094 EFFECT OF LOW-DOSE ASPIRIN ON THE INCIDENCE OF PREECLAMPSIA IN PREGNANT WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS**
C. Kohno, K. Kaneko, A. Murashima
(Tokyo, Japan)
- PO:07:095 ANALYSIS OF THE ASSOCIATION BETWEEN MATERNAL AND CORD BLOOD IMMUNE CELL PROFILING WITH PREGNANCY OUTCOME USING MASS CYTOMETER IN PREGNANCIES WITH SYSTEMIC LUPUS ERYTHEMATOSUS**
A. Kitada¹, H. Tsuboi², T. Nakai¹, A. Nomura³, H. Toko², A. Ohyama², S. Abe², H. Miki², H. Asashima², Y. Kondo², I. Matsumoto², M. Okada¹
(¹Tokyo, Japan, ²Tsukuba, Japan, ³Ushiku, Japan)
- PO:07:096 PREDICTORS OF 30-DAY READMISSIONS IN PREGNANT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: THE ROLE OF SOCIAL DETERMINANTS OF HEALTH.**
S.S. Kannayiram¹, Y. Wu¹, L. Sammaritano¹, M. Lockshin¹, R. Caruana², D.W. Branch³, J. Salmon¹, B. Mehta¹
(¹New York, USA, ²Redmond, USA, ³Salt Lake City, USA)
- PO:07:097 FETAL MYOCARDITIS INDUCED BY MATERNAL SSA/SSB AUTOANTIBODIES: A RARE AND ATYPICAL MANIFESTATION OF NEONATAL LUPUS**
S. Mannarino, M. Lanna, V. Garella, G. Cecconi, I. Raso, A. Laoreti, F. Puricelli, A.L. Brucato
(Milan, Italy)

POSTERS

- PO:07:098 THERAPEUTIC DRUG MONITORING OF AZATHIOPRINE AND TACROLIMUS IN SLE PREGNANCIES: PRELIMINARY RESULTS FROM THE LEGACY COHORT**
R. Farhat, A. Mendel, I. Malhamé, J.Y.E. Lee, L. Ciofani,
S. Bernatsky, É. Vinet
(Montreal, Canada)
- PO:07:099 IS PATIENT-REPORTED HYDROXYCHLOROQUINE ADHERENCE A SUFFICIENT MEASURE OF ADHERENCE?**
J. Mathias, A. Eudy, C. Sims, L. Neil, M. Clowse
(Durham, USA)
- PO:07:100 SYSTEMIC LUPUS ERYTHEMATOSUS PREGNANCIES: TRENDS IN DISEASE MANAGEMENT AND MATERNAL – FETAL OUTCOME COMPARING TWO TIME PERIODS (1988-2012 VS 2013-2022)**
F. Crisafulli, A. Gatti, C. Sottili, M.G. Lazzaroni, M. Fredi, C. Nalli,
M. Filippini, M. Taglietti, S. Zatti, R. Orabona, F. Franceschini,
L. Andreoli, A. Tincani
(Brescia, Italy)
- PO:07:101 THE IMPACT OF ANTI-RO ANTIBODIES ON MATERNAL AND INFANT OUTCOME IN A ROMANIAN COHORT**
C. Alexandru¹, M. Bojinca¹, C. Poalelungi¹, M. Videnie¹, L. Duca²,
M. Agache¹, L. Groseanu¹, I. Ancuta¹, A. Bobirca¹
(¹Bucharest, Romania, ²Brasov, Romania)
- PO:07:102 SURVIVING THE STORMA CASE OF SEVERE LUPUS FLARE WITH DIFFUSE ALVEOLAR HEMORRHAGE AND LUPUS NEPHRITIS IN THE SETTING OF PREGNANCY AND SEPSIS**
S. Al Emadi, I. Al Sheikh, N. Hadwan, E. Sattii
(Doha, Qatar)

POSTERS

POSTER SESSION 8: PATIENT PERSPECTIVES: FAMILY PLANNING WITH RHEUMATIC DISEASES, THE ESSENTIAL ROLE OF TEAMWORK

Chairs: M. Clowse (Durham, USA), A. Tincani (Brescia, Italy)

PO:08:103 PERCEIVED DIGNITY IN PATIENTS WITH RHEUMATIC DISEASE

C. Skinner, F.R. Arevalo-Nieto, Y.K. Lerma-Martinez, M.A. Ponce-Santillan, A.M. Ortiz-Rios, M.E. Corral-Trujillo, J.A. Cardenas-de la Garza, L. Perez-Barbosa, D.A. Galarza-Delgado (Monterrey, Mexico)

PO:08:104 MOTHERHOOD AND FAMILY PLANNING BELIEFS IN WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES

C. Skinner, F.R. Arevalo-Nieto, Y.K. Lerma-Martinez, M.A. Ponce-Santillan, A.M. Ortiz-Rios, L. Perez-Barbosa, D.A. Galarza-Delgado (Monterrey, Mexico)

PO:08:105 KNOWLEDGE, ATTITUDES, AND INTENTION TOWARDS HPV VACCINATION AMONG REPRODUCTIVE-AGE WOMEN WITH RHEUMATIC DISEASES

C. Skinner, L. Perez-Barbosa, M.A. Ponce-Santillan, A.M. Ortiz-Rios, G. Rodriguez-Orozco, A.G. Rodriguez-Flores, A. Carrasco-Chapa, K.A. Chavez-Olivo, A.P. Romero-Avila, C.A. Rangel-García, M.F. Rodriguez-Ramos, M.E. Corral Trujillo, J.A. Cardenas-de la Garza, D.A. Galarza-Delgado (Monterrey, Mexico)

PO:08:106 ILLNESS COGNITION AND SELF-ESTEEM AS PREDICTORS OF QUALITY OF LIFE IN REPRODUCTIVE-AGE WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES

L. Perez-Barbosa, C. Skinner-Taylor, A.G. Rodriguez-Flores, G. Rodriguez-Orozco, M.A. Ponce-Santillan, A.M. Ortiz-Rios, K.A. Chavez-Olivo, A.P. Romero-Avila, V. De Hoyos-Perez, M.E. Corral Trujillo, J.A. Cardenas-de la Garza, D.A. Galarza-Delgado (Monterrey, Mexico)

POSTERS

- PO:08:107 ACCESS TO MEDICAL CARE CONTRIBUTES TO PSYCHOLOGICAL RESILIENCE IN WOMEN WITH RHEUMATIC DISEASES OF REPRODUCTIVE AGE**
N. Rosenberg, A. Mazzucato-Puchner, P. Mandl, V. Ritschl, T. Stamm, K. Rosta
(Vienna, Austria)
- PO:08:108 WOMEN WITH INFLAMMATORY ARTHRITIS: IMPROVING PRECONCEPTION COUNSELLING IN PATIENTS ON DISEASE MODIFYING THERAPY**
N. Moollan, C. O'Loughlin, R. Conway, G. Cunnane, M. Doran, F. O'Shea
(Dublin, Ireland)
- PO:08:109 DOES PREGNANCY TRIGGER THE STORM: A CASE OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)**
S. Gruber, A. Mazzucato-Puchner, K. Rosta
(Vienna, Austria)
- PO:08:110 IMPACT OF CONFLICTING INFORMATION ON THE USE OF ANTI-RHEUMATIC DRUGS IN PREGNANCY AND BREASTFEEDING: PERSPECTIVES OF HEALTHCARE PROVIDERS FROM THE GLOBAL PRAISE SURVEY**
C. Graversgaard¹, K. Schreiber^{1,2,3}, L. Andreoli^{1,4}
(¹Sønderborg, Denmark, ²Odense, Denmark, ³London, UK, ⁴Brescia, Italy)
- PO:08:111 HOW TO IMPROVE SEXUAL AND REPRODUCTIVE HEALTH CARE TO FEMALE AND MALE PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: THE EXPERIENCE OF A REPRODUCTIVE HEALTH COUNSELLING CLINIC**
E. Giacobbe, M.C. Gerardi, C. Gagliardi, N. Ughi, S. Benedetti, G. Di Raimondo, A. Ascione, M. Barichello, O.M. Epis
(Milan, Italy)
- PO:08:112 LIVING WITH PSORIATIC DISEASE IN KENYA - PATIENTS PERSPECTIVE AND FAMILY PLANNING**
O. Etomi¹, W. Gatherer²
(¹London, UK, ²Nairobi, Kenya)

SCIENTIFIC INFORMATION

Oral Presentations

The selected presenting authors are requested to upload their presentation (landscape format 16:9) on a USB drive or laptop and deliver it to the slide center (inside the plenary room) at least one hour before the beginning of the session. Each presentation should last no more than 7 minutes followed by 3 minutes of discussion.

Posters

All posters must have maximum dimensions of 120 x 150 cm (portrait format).

Please note that poster boards will be set up in Olympia Mancini 1 and must remain up throughout the Congress, so that participants will be able to view them at their convenience.

It is possible to hang out the posters from 12:00 pm on 8 May until the end of the congress.

The required materials for affixing the posters are provided in the room.

The Poster Tour will be held on 9 May at h. 12:55-14:10. Each author is kindly asked to remain beside the poster during this slot to be available for questions by the Chairs and any other delegate.

Please note that each presentation should last no more than 5 minutes (discussion included) and be very concise. The discussion will be handled by the chairs of each session.

Authors are responsible for retrieving their posters at the conclusion of the congress. Any posters left behind will be removed.

Curbside Consultations

These sessions encourage a spontaneous discussion of a difficult clinical case. The case is presented by a speaker who raises a few key questions. The experts give their opinion on the best diagnosis/treatment options and discuss the case among themselves as physicians often do in their daily practice (without any slides).

The case is not previously known by any of the discussants. The speaker's role is to ensure a lively conversation and cover the various approaches, as well as to involve the audience in the conversation.

The Debate Session

The purpose of the debate is to have an intense discussion on some of the most burning controversies related to a specific topic. The two sides of the debate will be defended by two leading experts in the field, and the discussion will be controlled by a moderator whose role is to ensure that all aspects of the debate are duly discussed, as well as to involve the audience in the conversation.

Abstract Book

All submitted abstracts, accepted as oral presentations or posters, and presented during the Conference, will be published under the terms of Frontiers in Lupus & Frontiers in Medicine Journals. The weblink to the abstract book will be available in electronic format, online and downloadable after the congress.

CME Accreditation



The 13th International Conference on Reproduction, Pregnancy and Rheumatic diseases, VIENNA, Austria 08/05/2025 - 10/05/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME[®]) with 15.0 European CME credits (ECMEC[®]s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME[®] credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME[®] credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME[®] for ECMEC[®]s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 22 of UEMS 2023.07.

In order to help you issue individual certificates to each participant, please find below the breakdown of ECMEC[®]s per day:

Date	Credit
08/05/2025	5.5
09/05/2025	6.5
10/05/2025	3.0

The EACCME[®] awards ECMEC[®]s on the basis of 0,5 ECMEC[®] for 30 minutes of CME with a maximum of 8 ECMEC[®]s per day. cf. Chapter XIII of UEMS 2023.07.

Attendance is monitored through a scanner device in order to check learner's entrance/exit each day (the presence is a main requirement to obtain credits).

All the participants will receive, after the congress, the instructions to access an online platform through which they will be able to download the CME certificate, upon completion of the UEMS evaluation form.

CME Provider - AIM Education - Provider n. 93



Via E. Forlanini 23

20134 Milan, Italy

Tel. +39 02 56601.1

cme@aimgroup.eu

www.aimeducation.it

GENERAL INFORMATION

Congress Venue



Austria Trend Hotel Savoyen Vienna

Rennweg 16
1030 Wien, Austria

How to reach the venue

The Austria Trend Hotel Savoyen Vienna is centrally located in the embassy district, near the Belvedere Palace and Botanical Gardens, and is easily accessible by various transport options.

By Flight

Vienna Airport offers convenient connections to public transport. The venue can be reached by train, bus, or taxi:

- Train: Take the REX7 or S7 trains to Wien Rennweg (about 20 minutes), followed by a 3-minute walk.
- Taxi: Available outside the airport with a fixed fare of €42 (for up to 4 passengers).
- Ride-sharing: Uber and Bolt are also available.

By Train

The venue is a 3-minute walk from Wien Rennweg station and a 19-minute walk from Wien Hauptbahnhof (Vienna Central Station). Alternatively, take a train from Hauptbahnhof to Wien Rennweg (about 10 minutes).

By Car

The venue is easily reachable via major highways (A1, A2, A4) and follows straightforward routes towards the city center and Rennweg.

Parking

A garage is available directly at the hotel, with a daily fee of €18.

Accommodation

The Organizing Secretariat has reserved a limited number of rooms for the attendees at the Lindner Hotel Vienna Am Belvedere (Rennweg 12 - 1030 Wien, Austria), located a few steps away from the congress venue.

Organizing Secretariat



AIM Group International - Milan Office
Viale Enrico Forlanini 23
20134 Milan, Italy
Ph. +39 02 566011
rheumapreg2025@aimgroup.eu

Secretariat and Registration Desk

The registration desks will be open according to the following timetable:

- Thursday, 8 May 2025 h. 12:00 - 19:30
- Friday, 9 May 2025 h. 07:45 - 18:00
- Saturday, 10 May 2025 h. 08:00 - 13:40

Admission

All participants are kindly requested to collect their badge at the registration desk and wear it during all congress activities. The badge will allow you to access the scientific sessions, the exhibition area, coffee breaks and lunch.

Language

The official language is English. No simultaneous translation will be provided.

Certificate of Attendance

Participants will be able to download and print the certificate of attendance upon completion of the online evaluation form through a dedicated platform. The instructions will be sent by e-mail after the Congress.

Conference Opening

The Conference Opening will take place on 8 May at h. 13:00 in the Olympia Mancini 2+3 Room. The Opening Lecture will be held at h. 19:05 in the same room.

Coffee Breaks and Lunch

Coffee breaks will be offered in the foyer according to the following timetable:

- Thursday, 8 May 2025 h. 15:55 - 16:25
- Friday, 9 May 2025 h. 10:40 - 11:10 | h. 16:30 - 17:00
- Saturday, 10 May 2025 h. 10:15 - 10:45

On Friday, 9 May 2025, at h. 12:10 - 12:55, a buffet lunch will be served in the same area.

Congress Dinner

Friday, 9 May 2025, at h. 19:00

Wiener Rathaus – Vienna City Hall



Entrance: Lichtenfelsgasse 2, 1010 Vienna

The dinner is reserved for the Faculty and the delegates who have bought the ticket – 110 € VAT included.

Please note that the number of participants for this event is subject to limited availability. We invite you to check at the registration desk if there are any additional seats available.

Registration

Registration Fees (all fees are 20% VAT included)

	LATE REGISTRATION FEES from April 25 th , 2025 and on-site
Delegate	€ 500,00
Trainees, Students * and Health Professionals **	€ 200,00
Developing Countries ***	€ 200,00
Daily registration fee ****	€ 170,00

* In order to benefit from the special fee, a submission of your status confirmation must be shown at the registration desk (i.e. approval letter signed by the Head of Department or copy of your status ID).

** Nurses, physiotherapists, occupational therapists and other nearby allied health professionals. A letter of confirmation of your status from the Head of Unit or Institute must be handed over at the registration desk.

*** Lower and Middle Country classification as listed and defined according to the World Bank website.

**** Valid for "One Day" access. This fee is valid only for delegates (no trainees, no developing countries).

The delegate fee includes:

- Admission to the scientific sessions
- Congress bag holding all the meeting materials
- Certificate of attendance
- Access to the poster area
- Coffee breaks and lunch, according to the programme

Payment

On-site it's only possible to pay by credit card.

All major credit cards are accepted (VISA, Mastercard/Eurocard, American Express).

Name Changes

After 8 April 2025, sponsors who wish to make name changes will be charged of a handling fee of € 50,00 (VAT 20% included) per name change. A new registration form for each replacement participant will be required before the name change can be processed. Individuals may make name changes only in exceptional cases.

Cancellation Policy

Notification of cancellation must be sent in writing to the organizing secretariat (rheumapreg2025@aimgroup.eu).

Cancellations will be accepted until 8 April 2025, with a refund of all prepaid fees except for a 30% administration charge. No refunds will be made for cancellations received after this date.

Unexpected cancellation of the event or impossibility to hold it

In the unlikely case that the 13th RheumaPreg Conference 2025 cannot be held in whole or in part due to any event beyond the Organisers' control or force majeure (such as riot, fire, explosion, accident, flood, earthquake, sabotage, strikes, acts of any government, etc) the Congress Organisers cannot be held liable for any damage, cost, or loss incurred, such as registration fee, transportation and accommodation costs, or any other direct or indirect loss or consequential damage.

Privacy Policy

The information on the processing of personal data in accordance with European Regulation n. 679 of 2016 has been consulted during the registration process and/or received by e-mail.

For further information, please contact the Organizing Secretariat.

UCB SATELLITE SYMPOSIUM

Saturday, 10 May 2025

08:30-09:30 **INDUSTRY-SPONSORED SYMPOSIUM**
EMPOWERING WOMEN'S CHOICES: OPTIMISING CARE
FOR WOMEN OF CHILDBEARING AGE WITH CHRONIC
INFLAMMATORY DISEASE

Chair: J. Salmon (New York, USA)

08:30-08:40 **Welcome and Introduction**

J. Salmon (New York, USA)

08:40-08:55 **What do women want? Early conversations around**
treatment options for chronic inflammatory disease

L. Bortey, O. Etomi (London, UK)

08:55-09:05 **Innovation with Fc-free expertise**

O. Etomi (London, UK)

09:05-09:15 **Crossing the placental barrier into the unknown –**
immunophenotyping of the neonate

A. Pluma Sanjurjo (Barcelona, Spain)

09:15-09:30 **Faculty Discussion and Q&A**

O. Etomi (London, UK)

A. Pluma Sanjurjo (Barcelona, Spain)

J. Salmon (New York, USA)



UCB at RheumaPreg 2025

Discover our commitment to advancing research and optimising treatment for women of childbearing age with chronic inflammatory disease

Connect With Us at Our Booths

You will find us by the entrance to the main plenary room




Join Our Symposium

Empowering Women's Choices: Optimising Care for Women of Childbearing Age with Chronic Inflammatory Disease

10th May, 08:30–09.30

Chaired by: Dr Jane Salmon




Visit the Poster Hall

Poster Session 6

9th May, 12:55–14.10

OR Visit the poster at any time in the poster hall



UCB is proud to, once again, be a platinum sponsor of the RheumaPreg congress in 2025!

ACKNOWLEDGEMENTS

Platinum Sponsor



Supporters

CSL Behring



GSK

